New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials
We are pleased to announce a grant collaboration with Dr. Bryan Spring, of Northeastern University. Recently, we sat down with Dr. Spring to understand the value sees with Cellaria cell models when compared to conventional cell lines for pancreatic and ovarian cancer. The ultimate goal of his lab is to reduce cancer recurrence and mortality by establishing new approaches for personalized medicine that address tumor heterogeneity, drug-resistance and molecular mechanisms of treatment.
Diabetes research requires the use of insulin-secreting islets of Langerhans that are derived from the pancreas of a human or a mouse. Islets of Langerhans are tiny cell clusters in the pancreas that are responsible for insulin production. When these cells malfunction, diabetes occurs. Whole islets, or the beta cells derived from islets, are a critical component in diabetes research. For example, they are required when using high-throughput screens (HTS) to identify the next active compound that would lead to an increase in newly-formed beta-cells or to reduce the chance of beta-cell death. Unfortunately, isolation of islets from donor tissues is a technically challenging process, which limits the number of islets available from the individual donor. Also, it is often complicated by the lack of access to donor pancreas tissue.